Emily AG Faherty

Dr. Emily AG Faherty

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Revista Panamericana de Salud Pública
Verified
Journal Article
Open access
PDF file
Claudia  Munoz-ZanziClaudia Munoz-Zanzi
Claudia Munoz-Zanzi
EFEmily AG Faherty
Emily AG Faherty
BMBozena M. Morawski
Bozena M. Morawski
KBKimberly Bonner
Kimberly Bonner
FCFederico Costa
Federico Costa
MSMaria Cristina Schneider
Maria Cristina Schneider
Objective. This review describes the geographic and temporal distribution of, detection methods for, and other epidemiological features of published leptospirosis outbreaks, with the aim of informing efforts to standardize outbreak-reporting practices. Methods. We conducted a systematic review of leptospirosis outbreaks reported in the scientific literature and ProMED during 1970–2012. Predefined criteria were used to identify and classify outbreaks and a standard form was used to extract information. Results. During 1970–2012, we identified 318 outbreaks (average: 7 outbreaks/year; range: 1–19). Most outbreaks were reported in the Latin America and the Caribbean region (36%), followed by Southern Asia (13%), and North America (11%). Most outbreaks were located in tropical and subtropical ecoregions (55%). Quality classification showed that there was clear description of laboratory-confirmed cases in 40% of outbreaks. Among those, the average outbreak size was 82 cases overall (range: 2–2 259) but reached 253 cases in tropical/subtropical ecoregions. Common risk factors included outdoor work activities (25%), exposure to floodwaters (23%), and recreational exposure to water (22%). Epidemiologic investigation was conducted in 80% of outbreaks, mainly as case interviews. Case fatality was 5% overall (range: 0%–60%). Conclusions. Outbreak reporting increased over the study period with outbreaks covering tropical and non-tropical regions. Outbreaks varied by size, setting, and risk factors; however, data reviewed often had limited information regarding diagnosis and epidemiology. Guidelines are recommended to develop standardized procedures for diagnostic and epidemiological investigations during an outbreak and for reporting.

10 December 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
EBEmily A Burger
Emily A Burger
IKInge M C M de Kok
Inge M C M de Kok
EFEmily AG Faherty
Emily AG Faherty
JKJames Killen
James Killen
KCKaren Canfell
Karen Canfell
JKJane J Kim
Jane J Kim
Background: The natural history of human papillomavirus (HPV)-induced cervical cancer (CC) is not directly observable, yet the age of HPV acquisition and duration of preclinical disease (dwell time) influences the effectiveness of alternative preventive policies. We performed a Cancer Intervention and Surveillance Modeling Network (CISNET) comparative modeling analysis to characterize the age of acquisition of cancer-causing HPV infections and implied dwell times for distinct phases of cervical carcinogenesis. Methods: Using four CISNET-cervical models with varying underlying structures but fit to common US epidemiological data, we estimated the age of acquisition of causal HPV infections and dwell times associated with three phases of cancer development: HPV, high-grade precancer, and cancer sojourn time. We stratified these estimates by HPV genotype under both natural history and CC screening scenarios, because screening prevents cancer development that affects the mix of detected cancers. Results: The median time from HPV acquisition to cancer detection ranged from 17.5 to 26.0 years across the four models. Three models projected that 50% of unscreened women acquired their causal HPV infection between ages 19 and 23 years, whereas one model projected these infections occurred later (age 34 years). In the context of imperfect compliance with US screening guidelines, the median age of causal infection was 4.4–15.9 years later compared with model projections in the absence of screening. Conclusions: These validated CISNET-CC models, which reflect some uncertainty in the development of CC, elucidate important drivers of HPV vaccination and CC screening policies and emphasize the value of comparative modeling when evaluating public health policies.

23 June 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
EFEmily AG Faherty
Emily AG Faherty
THTaylor Holly
Taylor Holly
YOYasmin P Ogale
Yasmin P Ogale
GCGordon Crisler
Gordon Crisler
ABAshley Becht
Ashley Becht
ITIrina Tabidze
Irina Tabidze
This report describes an investigation into mpox clusters among previously vaccinated individuals in Chicago.

20 December 2023 in Science of The Total Environment
Verified
Journal Article
Closed access
EFEmily AG Faherty
Emily AG Faherty
DYDeniz Yuce
Deniz Yuce
CKColin Korban
Colin Korban
KBKelley Bemis
Kelley Bemis
RKRishi Kowalski
Rishi Kowalski
MPMassimo Pacilli
Massimo Pacilli

1 May 2020 in Medical Decision Making
Verified
Journal Article
Open access
PDF file
IKInge M. C. M. de Kok
Inge M. C. M. de Kok
EBEmily A. Burger
Emily A. Burger
SNSteffie K. Naber
Steffie K. Naber
KCKaren Canfell
Karen Canfell
JKJames Killen
James Killen
MBMarjolein van Ballegooijen
Marjolein van Ballegooijen
Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease that occurred after screening, 2) disease that was present but not screen detected, or 3) disease that was screen detected but not successfully treated. We examined the relative contributions of each of these using 4 Cancer Intervention and Surveillance Modeling Network (CISNET) models. Methods. The maximum clinical incidence reduction (MCLIR) method compares changes in the number of clinically detected cervical cancers and mortality among 4 scenarios: 1) no screening, 2) one-time perfect screening at age 45 that detects all existing disease and delivers perfect (i.e., 100% effective) treatment of all screen-detected disease, 3) one-time realistic-sensitivity cytological screening and perfect treatment of all screen-detected disease, and 4) one-time realistic-sensitivity cytological screening and realistic-effectiveness treatment of all screen-detected disease. Results. Predicted incidence reductions ranged from 55% to 74%, and mortality reduction ranged from 56% to 62% within 15 years of follow-up for scenario 4 across models. The proportion of deaths due to disease not detected by screening differed across the models (21%–35%), as did the failure of treatment (8%–16%) and disease occurring after screening (from 1%–6%). Conclusions. The MCLIR approach aids in the interpretation of variability across model results. We showed that the reasons why screening failed to prevent cancers and deaths differed between the models. This likely reflects uncertainty about unobservable model inputs and structures; the impact of this uncertainty on policy conclusions should be examined via comparing findings from different well-calibrated and validated model platforms.

3 April 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EFEmily AG Faherty
Emily AG Faherty
THTaylor Holly
Taylor Holly
YOYasmin P Ogale
Yasmin P Ogale
HSHillary Spencer
Hillary Spencer
ABAshley M Becht
Ashley M Becht
ITIrina Tabidze
Irina Tabidze
Background: After months of few mpox cases, an increase in cases was reported in Chicago during May 2023, predominantly among fully vaccinated (FV) patients. We investigated the outbreak scope, differences between vaccinated and unvaccinated patients, and hypotheses for monkeypox virus (MPXV) infection after vaccination. Methods: We interviewed patients and reviewed medical records to assess demographic, behavioral, and clinical characteristics; mpox vaccine status; and vaccine administration routes. We evaluated serum antibody levels after infection and compared patient viral genomes with MPXV sequences in available databases. We discussed potential vaccine compromise with partners who manufactured, handled, and administered the vaccine associated with breakthrough infections. Results: During 18 March–27 June 2023, we identified 49 mpox cases; 57% of these mpox patients were FV. FV patients received both JYNNEOS doses subcutaneously (57%), intradermally (7%), or via heterologous administration (36%). FV patients had more median sex partners (3; interquartile range [IQR] = 1–4) versus not fully vaccinated patients (1; IQR = 1–2). Thirty-six of 37 sequenced specimens belonged to lineage B.1.20 of clade IIb MPXV, which did not demonstrate any amino acid changes relative to B.1, the predominant lineage from May 2022. Vaccinated patients demonstrated expected humoral antibody responses; none were hospitalized. No vaccine storage excursions were identified. Approximately 63% of people at risk for mpox in Chicago were FV during this period. Conclusions: Our investigation indicated that cases were likely due to frequent behaviors associated with mpox transmission, even with relatively high vaccine effectiveness and vaccine coverage. Cases after vaccination might occur in similar populations.